A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)
Hepatitis C
About this trial
This is an interventional treatment trial for Hepatitis C
Eligibility Criteria
Inclusion Criteria:
- Baseline health is stable.
- Has a clinical diagnosis of chronic HCV infection.
Exclusion Criteria:
- Has a history of stroke or chronic seizures.
- Has a history of cancer.
- Has a history of human immunodeficiency virus (HIV) infection.
- Has had major surgery, donated blood or participated in another investigational study within the past 3 months.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm 10
Arm 11
Arm 12
Arm 13
Arm 14
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
400 mg Grazoprevir - GT1
600 mg Grazoprevir - GT1
800 mg Grazoprevir - GT1
400 mg Grazoprevir - GT3
600 mg Grazoprevir - GT3
800 mg Grazoprevir - GT3
200 mg Grazoprevir - GT1
100 mg Grazoprevir - GT1
50 mg Grazoprevir - GT1
200 mg Grazoprevir - GT3
100 mg Grazoprevir - GT3
50 mg Grazoprevir - GT3
30 mg Grazoprevir - GT1
10 mg Grazoprevir - GT1
GT1 HCV-infected Participants: 400 mg Grazoprevir or Placebo
GT1 HCV-infected Participants: 600 mg Grazoprevir or Placebo
GT1 HCV-infected Participants: 800 mg Grazoprevir or Placebo
GT3 HCV-infected Participants: 400 mg Grazoprevir or Placebo
GT3 HCV-infected Participants: 600 mg Grazoprevir or Placebo
GT3 HCV-infected Participants: 800 mg Grazoprevir or Placebo
GT1 HCV-infected Participants: 200 mg Grazoprevir or Placebo
GT1 HCV-infected Participants: 100 mg Grazoprevir or Placebo
GT1 HCV-infected Participants: 50 mg Grazoprevir or Placebo
GT3 HCV-infected Participants: 200 mg Grazoprevir or Placebo
GT3 HCV-infected Participants: 100 mg Grazoprevir or Placebo
GT3 HCV-infected Participants: 50 mg Grazoprevir or Placebo
GT1 HCV-infected Participants: 30 mg Grazoprevir or Placebo
GT1 HCV-infected Participants: 10 mg Grazoprevir or Placebo